Changes in hypothalamus-pituitary-adrenal axis following transient ischemic attack

Angiology

Volumn 65, Issue 8, 2014, Pages 723-732

  Radak, Djordje ^a   Resanovic, Ivana ^b   Isenovic, Esma R ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

acute brain ischemia; hypothalamic pituitary adrenal axis; stroke; transient ischemic attack

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; PROTEINASE ACTIVATED RECEPTOR; VASOPRESSIN;

ADRENAL CORTEX FUNCTION; AGED; ARTICLE; BRAIN BLOOD FLOW; BRAIN DAMAGE; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; ENDOPLASMIC RETICULUM; EXCITOTOXICITY; FEMALE; HEART INFARCTION; HORMONE RELEASE; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PROGNOSIS; TRANSIENT ISCHEMIC ATTACK;

ACUTE BRAIN ISCHEMIA; HYPOTHALAMIC-PITUITARY-ADRENAL AXIS; STROKE; TRANSIENT ISCHEMIC ATTACK;

ANIMALS; ARGININE VASOPRESSIN; CORTICOTROPIN-RELEASING HORMONE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; ISCHEMIC ATTACK, TRANSIENT; PITUITARY-ADRENAL SYSTEM;

EID: 84905898967     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319713503487     Document Type: Article

References (134)

1. Lee S, Shafe AC, Cowie MR. UK stroke incidence, mortality and cardiovascular risk management 1999-2008: time-trend analysis from the General Practice Research Database. BMJ Open. 2011 ; 1 (2). e000269
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation. 2012 ; 125 (1). e2 - e220
3. Syme PD, Byrne AW, Chen R, Devenny R, Forbes JF. Community-based stroke incidence in a Scottish population: the Scottish Borders Stroke Study. Stroke. 2005 ; 36 (9). 1837-1843
4. Milionis HJ, Liberopoulos E, Goudevenos J, Bairaktari ET, Seferiadis K, Elisaf MS. Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals. Int J Cardiol. 2005 ; 99 (2). 269-275
5. Hall MJ, Levant S, DeFrances CJ. Hospitalization for stroke in U.S. hospitals, 1989-2009. NCHS Data Brief. 2012 ; (95). 1-8
6. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet. 2008 ; 371 (9624). 1612-1623
7. Breton RR, Rodríguez JC. Excitotoxicity and oxidative stress in acute ischemic stroke. Acute Ischemic Stroke. 2012 ;:
8. Kimura K, Minematsu K, Yasaka M, Wada K, Yamaguchi T. The duration of symptoms in transient ischemic attack. Neurology. 1999 ; 52 (5). 976-980
9. Kaur J, Arora S, Singh B, Thakur LC, Gambhir J, Prabhu KM. Role of oxidative stress in pathophysiology of transient ischemic attack and stroke. Int J Biol Med Res. 2011 ; 2 (3). 611-615
10. Atanassova PA, Chalakova NT, Dimitrov BD. Major vascular events after transient ischaemic attack and minor ischaemic stroke: post hoc modelling of incidence dynamics. Cerebrovasc Dis. 2008 ; 25 (3). 225-233
11. Braughler JM, Hall ED. Central nervous system trauma and stroke. I. Biochemical considerations for oxygen radical formation and lipid peroxidation. Free Radic Biol Med. 1989 ; 6 (3). 289-301
12. Arumugam TV, Granger DN, Mattson MP. Stroke and T-cells. Neuromol Med. 2005 ; 7 (3). 229-242
13. Mattson MP, Duan W, Pedersen WA, Culmsee C. Neurodegenerative disorders and ischemic brain diseases. Apoptosis. 2001 ; 6 (1-2). 69-81
14. Woodruff TM, Thundyil J, Tang SC, Sobey CG, Taylor SM, Arumugam TV. Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Mol Neurodegener. 2011 ; 6 (1). 11
15. Lakhan SE, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med. 2009 ; 7: 97
16. Raichle ME. The pathophysiology of brain ischemia. Ann Neurol. 1983 ; 13 (1). 2-10
17. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999 ; 22 (9). 391-397
18. Andrew S, James L. Vasopressin and its role in critical care. Oxford J. 2008 ; 8 (4). 134-113
19. Neidert S, Katan M, Schuetz P, et al. Anterior pituitary axis hormones and outcome in acute ischaemic stroke. J Intern Med. 2011 ; 269 (4). 420-432
20. Olsson T, Marklund N, Gustafson Y, Nasman B. Abnormalities at different levels of the hypothalamic-pituitary-adrenocortical axis early after stroke. Stroke. 1992 ; 23 (11). 1573-1576
21. Fassbender K, Schmidt R, Mossner R, Daffertshofer M, Hennerici M.. Pattern of activation of the hypothalamic-pituitary-adrenal axis in acute stroke. Relation to acute confusional state, extent of brain damage, and clinical outcome. Stroke. 1994 ; 25 (6). 1105-1108
22. Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B. Prognostic relevance of pathological sympathetic activation after acute thromboembolic stroke. Neurology. 2001 ; 57 (5). 833-838
23. Marrocco-Trischitta MM, Tiezzi A, Svampa MG, et al. Perioperative stress response to carotid endarterectomy: the impact of anesthetic modality. J Vasc Surg. 2004 ; 39 (6). 1295-1304
24. Wilmore DW Textbook of Surgery: The Biological Basis of Modern Surgical Practise. 14 th ed. WB Saunders: Philadelphia, PA; 1991:19-33. DC Sabiston, ed. WB Saunders: Philadelphia, PA ; 1991: 19-33.
25. Moustafa RR, Baron JC. Pathophysiology of ischaemic stroke: insights from imaging, and implications for therapy and drug discovery. Br J Pharmacol. 2008 ; 153 (suppl 1). S44 - S54
26. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci. 2003 ; 4 (5). 399-415
27. Erecinska M, Silver IA. Tissue oxygen tension and brain sensitivity to hypoxia. Respir Physiol. 2001 ; 128 (3). 263-276
28. Heiss WD. Flow thresholds of functional and morphological damage of brain tissue. Stroke. 1983 ; 14 (3). 329-331
29. Hansen AJ, Nedergaard M. Brain ion homeostasis in cerebral ischemia. Neurochem Pathol. 1988 ; 9: 195-209
30. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol. 1986 ; 19 (2). 105-111
31. Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci. 1990 ; 13: 171-182
32. Lipton P. Ischemic cell death in brain neurons. Physiol Rev. 1999 ; 79 (4). 1431-1568
33. He M, Chen M, Wang J, et al. Relationship between glutamate in the limbic system and hypothalamus-pituitary-adrenal axis after middle cerebral artery occlusion in rats. Chin Med J (Engl). 2003 ; 116 (10). 1492-1496
34. Milton SL, Thompson JW, Lutz PL. Mechanisms for maintaining extracellular glutamate levels in the anoxic turtle striatum. Am J Physiol Regul Integr Comp Physiol. 2002 ; 282 (5). R1317 - R1323
35. Yan P, Xu J, Li Q, et al. Glucocorticoid receptor expression in the spinal cord after traumatic injury in adult rats. J Neurosci. 1999 ; 19 (21). 9355-9363
36. Chen B, Friedman B, Whitney MA, et al. Thrombin activity associated with neuronal damage during acute focal ischemia. J Neurosci. 2012 ; 32 (22). 7622-7631
37. Borissoff JI, Spronk HM, Heeneman S, ten Cate H. Is thrombin a key player in the 'coagulation-atherogenesis' maze?. Cardiovasc Res. 2009 ; 82 (3). 392-403
38. Borissoff JI, Heeneman S, Kilinc E, et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation. 2010 ; 122 (8). 821-830
39. Sugg RM, Malkoff MD, Noser EA, et al. Endovascular recanalization of internal carotid artery occlusion in acute ischemic stroke. AJNR Am J Neuroradiol. 2005 ; 26 (10). 2591-2594
40. Shahar E, Chambless LE, Rosamond WD, et al. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2003 ; 34 (3). 623-631
41. Bots ML, Elwood PC, Nikitin Y, et al. Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health. 2002 ; 56 (suppl 1). i19 - i24
42. Thanvi B, Robinson T. Complete occlusion of extracranial internal carotid artery: clinical features, pathophysiology, diagnosis and management. Postgrad Med J. 2007 ; 83 (976). 95-99
43. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 ; 324 (7329). 71-86
44. Tu WJ, Dong X, Zhao SJ, Yang DG, Chen H J Neuroendocrinol. 2013 :
45. Weidenfeld J, Leker RR, Gai N, Teichner A, Bener D, Ovadia H. The function of the adrenocortical axis in permanent middle cerebral artery occlusion: effect of glucocorticoids on the neurological outcome. Brain Res. 2011 ; 1407: 90-96
46. Smith SM, Vale WW. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues Clin Neurosci. 2006 ; 8 (4). 383-395
47. Stuller KA, Jarrett B, DeVries AC. Stress and social isolation increase vulnerability to stroke. Exp Neurol. 2012 ; 233 (1). 33-39
48. Slowik A, Turaj W, Pankiewicz J, Dziedzic T, Szermer P, Szczudlik A. Hypercortisolemia in acute stroke is related to the inflammatory response. J Neurol Sci. 2002 ; 196 (1-2). 27-32
49. Johansson A, Olsson T, Carlberg B, Karlsson K, Fagerlund M. Hypercortisolism after stroke-partly cytokine-mediated?. J Neurol Sci. 1997 ; 147 (1). 43-47
50. Ribe EM, Serrano-Saiz E, Akpan N, Troy CM. Mechanisms of neuronal death in disease: defining the models and the players. Biochem J. 2008 ; 415 (2). 165-182
51. Amantea D, Nappi G, Bernardi G, Bagetta G, Corasaniti MT. Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS J. 2009 ; 276 (1). 13-26
52. Offner H, Vandenbark AA, Hurn PD. Effect of experimental stroke on peripheral immunity: CNS ischemia induces profound immunosuppression. Neuroscience. 2009 ; 158 (3). 1098-1111
53. Keller-Wood ME, Dallman MF. Corticosteroid inhibition of ACTH secretion. Endocr Rev. 1984 ; 5 (1). 1-24
54. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 1981 ; 213 (4514). 1394-1397
55. Rivier C, Vale W. Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature. 1983 ; 305 (5932). 325-327
56. Chen Y, Bender RA, Frotscher M, Baram TZ. Novel and transient populations of corticotropin-releasing hormone-expressing neurons in developing hippocampus suggest unique functional roles: a quantitative spatiotemporal analysis. J Neurosci. 2001 ; 21 (18). 7171-7181
57. Chen A, Perrin M, Brar B, et al. Mouse corticotropin-releasing factor receptor type 2alpha gene: isolation, distribution, pharmacological characterization and regulation by stress and glucocorticoids. Mol Endocrinol. 2005 ; 19 (2). 441-458
58. Westphal NJ, Seasholtz AF. CRH-BP: the regulation and function of a phylogenetically conserved binding protein. Front Biosci. 2006 ; 11: 1878-1891
59. Srivastava RK, Akinbami MA, Mann DR. Acute immobilization stress alters LH and ACTH release in response to administration of N-methyl-d,l-aspartic acid in peripubertal and adult male rats. Life Sci. 1995 ; 56 (18). 1535-1543
60. Pavlov VA, Wang H, Czura CJ, Friedman SG, Tracey KJ. The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. Mol Med. 2003 ; 9 (5-8). 125-134
61. Chautard T, Boudouresque F, Guillaume V, Oliver C. Effect of excitatory amino acid on the hypothalamo-pituitary-adrenal axis in the rat during the stress-hyporesponsive period. Neuroendocrinology. 1993 ; 57 (1). 70-78
62. Tsigos C, Chrousos GP. Physiology of the hypothalamic-pituitary-adrenal axis in health and dysregulation in psychiatric and autoimmune disorders. Endocrinol Metab Clin North Am. 1994 ; 23 (3). 451-466
63. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev. 2000 ; 21 (1). 55-89
64. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab. 2009 ; 94 (8). 2692-2701
65. Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev. 1997 ; 18 (3). 306-360
66. Kovacs KJ, Foldes A, Sawchenko PE. Glucocorticoid negative feedback selectively targets vasopressin transcription in parvocellular neurosecretory neurons. J Neurosci. 2000 ; 20 (10). 3843-3852
67. Watts AG. Glucocorticoid regulation of peptide genes in neuroendocrine CRH neurons: a complexity beyond negative feedback. Front Neuroendocrinol. 2005 ; 26 (3-4). 109-130
68. Jacobson L, Sapolsky R. The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. Endocr Rev. 1991 ; 12 (2). 118-134
69. McEwen BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Res. 2000 ; 886 (1-2). 172-189
70. Van den Berghe G. The neuroendocrine response to stress is a dynamic process. Best Pract Res Clin Endocrinol Metab. 2001 ; 15 (4). 405-419
71. Dekker MJHJ Pre-Receptor Regulatie Van Cortisol in Hypothalamus-Hypofyse- Bijnier as Functie en Metabolisme. Rotterdam, the Netherlands: Erasmus University ; 2011 :
72. Delaunay F, Khan A, Cintra A, et al. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest. 1997 ; 100 (8). 2094-2098
73. Duclos M, Marquez Pereira P, Barat P, Gatta B, Roger P. Increased cortisol bioavailability, abdominal obesity, and the metabolic syndrome in obese women. Obes Res. 2005 ; 13 (7). 1157-1166
74. Friedman TC, Mastorakos G, Newman TD, et al. Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM. Endocr J. 1996 ; 43 (6). 645-655
75. Bjorntorp P, Rosmond R. Hypothalamic origin of the metabolic syndrome X. Ann N Y Acad Sci. 1999 ; 892: 297-307
76. Antonawich FJ, Miller G, Rigsby DC, Davis JN. Regulation of ischemic cell death by glucocorticoids and adrenocorticotropic hormone. Neuroscience. 1999 ; 88 (1). 319-325
77. Virgin CE, Ha TP, Packan DR, et al. Glucocorticoids inhibit glucose transport and glutamate uptake in hippocampal astrocytes: implications for glucocorticoid neurotoxicity. J Neurochem. 1991 ; 57 (4). 1422-1428
78. Bratt AM, Kelley SP, Knowles JP, et al. Long term modulation of the HPA axis by the hippocampus. Behavioral, biochemical and immunological endpoints in rats exposed to chronic mild stress. Psychoneuroendocrinology. 2001 ; 26 (2). 121-145
79. Olsson T. Urinary free cortisol excretion shortly after ischaemic stroke. J Intern Med. 1990 ; 228 (2). 177-181
80. Gustafson Y, Olsson T, Eriksson S, Asplund K, Bucht G. Acute confusional states (delirium) in stroke patients. Cerebrovasc Dis. 1991 ; 1: 257-264
81. Anne M, Juha K, Timo M, et al. Neurohormonal activation in ischemic stroke: effects of acute phase disturbances on long-term mortality. Curr Neurovasc Res. 2007 ; 4 (3). 170-175
82. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998 ; 339 (5). 321-328
83. Makikallio AM, Makikallio TH, Korpelainen JT, et al. Natriuretic peptides and mortality after stroke. Stroke. 2005 ; 36 (5). 1016-1020
84. Kim SH, Lee JY, Park SH, et al. Plasma B-type natriuretic peptide level in patients with acute cerebral infarction according to infarction subtype and infarction volume. Int J Med Sci. 2013 ; 10 (1). 103-109
85. Cao LH, Yang XL. Natriuretic peptides and their receptors in the central nervous system. Prog Neurobiol. 2008 ; 84 (3). 234-248
86. Mair J. Biochemistry of B-type natriuretic peptide - where are we now?. Clin Chem Lab Med. 2008 ; 46 (11). 1507-1514
87. LaPointe MC. Molecular regulation of the brain natriuretic peptide gene. Peptides. 2005 ; 26 (6). 944-956
88. Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL. Biology of the natriuretic peptides. Am J Cardiol. 2008 ; 101 (3A). 3-8
89. Porzionato A, Macchi V, Rucinski M, Malendowicz LK, De Caro R. Natriuretic peptides in the regulation of the hypothalamic-pituitary-adrenal axis. Int Rev Cell Mol Biol. 2010 ; 280: 1-39
90. Katoh C, Osanai T, Tomita H, Okumura K. Brain natriuretic peptide is released from human astrocytoma cell line U373MG under hypoxia: a possible role in anti-apoptosis. J Endocrinol. 2011 ; 208 (1). 51-57
91. Nedergaard M. Mechanisms of brain damage in focal cerebral ischemia. Acta Neurol Scand. 1988 ; 77 (2). 81-101
92. Bambrick L, Kristian T, Fiskum G. Astrocyte mitochondrial mechanisms of ischemic brain injury and neuroprotection. Neurochem Res. 2004 ; 29 (3). 601-608
93. Chen Y, Swanson RA. Astrocytes and brain injury. J Cereb Blood Flow Metab. 2003 ; 23 (2). 137-149
94. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke.. 1993 ; 24 (1). 35-41
95. Myers MG, Norris JW, Hachinski VC, Weingert ME, Sole MJ. Cardiac sequelae of acute stroke. Stroke. 1982 ; 13 (6). 838-842
96. Schwarz S, Schwab S, Klinga K, Maser-Gluth C, Bettendorf M. Neuroendocrine changes in patients with acute space occupying ischaemic stroke. J Neurol Neurosurg Psychiatry. 2003 ; 74 (6). 725-727
97. Clerico A, Giannoni A, Vittorini S, Passino C. Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol. 2011 ; 301 (1). H12 - H20
98. Vakili A, Kataoka H, Plesnila N. Role of arginine vasopressin V1 and V2 receptors for brain damage after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2005 ; 25 (8). 1012-1019
99. Antoni FA. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol. 1993 ; 14 (2). 76-122
100. Rosenberg GA, Scremin O, Estrada E, Kyner WT. Arginine vasopressin V1-antagonist and atrial natriuretic peptide reduce hemorrhagic brain edema in rats. Stroke. 1992 ; 23 (12). 1767-1773
101. Bemana I, Nagao S. Treatment of brain edema with a nonpeptide arginine vasopressin V1 receptor antagonist OPC-21268 in rats. Neurosurgery. 1999 ; 44 (1). 148-154
102. Fernandez N, Martinez MA, Garcia-Villalon AL, Monge L, Dieguez G. Cerebral vasoconstriction produced by vasopressin in conscious goats: role of vasopressin V(1) and V(2) receptors and nitric oxide. Br J Pharmacol. 2001 ; 132 (8). 1837-1844
103. Cserr HF, Latzkovits L. A role for centrally-released vasopressin in brain ion and volume regulation: a hypothesis. Prog Brain Res. 1992 ; 91: 3-6
104. Buijs RM.. Intra- and extrahypothalamic vasopressin and oxytocin pathways in the rat. Pathways to the limbic system, medulla oblongata and spinal cord. Cell Tissue Res. 1978 ; 192 (3). 423-435
105. Riphagen CL, Pittman QJ. Arginine vasopressin as a central neurotransmitter. Fed Proc. 1986 ; 45 (9). 2318-2322
106. Brinton RE, Gee KW, Wamsley JK, Davis TP, Yamamura HI. Regional distribution of putative vasopressin receptors in rat brain and pituitary by quantitative autoradiography. Proc Natl Acad Sci USA. 1984 ; 81 (22). 7248-7252
107. Pearlmutter AF, Szkrybalo M, Kim Y, Harik SI. Arginine vasopressin receptors in pig cerebral microvessels, cerebral cortex and hippocampus. Neurosci Lett. 1988 ; 87 (1-2). 121-126
108. Kozniewska E, Szczepanska-Sadowska E. V2-like receptors mediate cerebral blood flow increase following vasopressin administration in rats. J Cardiovasc Pharmacol. 1990 ; 15 (4). 579-585
109. Kam PC, Williams S, Yoong FF. Vasopressin and terlipressin: pharmacology and its clinical relevance. Anaesthesia. 2004 ; 59 (10). 993-1001
110. Christensen H, Boysen G, Johannesen HH. Serum-cortisol reflects severity and mortality in acute stroke. J Neurol Sci. 2004 ; 217 (2). 175-180
111. Samuels MA. The brain-heart connection. Circulation. 2007 ; 116 (1). 77-84
112. Fantidis P. The role of the stress-related anti-inflammatory hormones ACTH and cortisol in atherosclerosis. Curr Vasc Pharmacol. 2010 ; 8 (4). 517-525
113. Pozzi AO, Bernardo E, Coronado MT, Punchard MA, Gonzalez P, Fantidis P. Acute arterial thrombosis in the absence of inflammation: the stress-related anti-inflammatory hormone ACTH participates in platelet-mediated thrombosis. Atherosclerosis. 2009 ; 204 (1). 79-84
114. Erem C, Nuhoglu I, Yilmaz M, et al. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels. J Endocrinol Invest. 2009 ; 32 (2). 169-174
115. Girolami A, Berti de Marinis G, Bonamigo E, Treleani M, Vettore S Clin Appl Thromb Hemost. 2012 :
116. Conner WE, Lin DS, Colvis C. Differential mobilization of fatty acids from adipose tissue. J Lipid Res. 1996 ; 37 (2). 290-298
117. Mikhailidis DP, Mikhailidis AM, Barradas MA, Dandona P. Effect of nonesterified fatty acids on the stability of prostacyclin activity. Metabolism. 1983 ; 32 (7). 717-721
118. Barradas MA, Mikhailidis DP, Dandona P. The effect of non-esterified fatty acids on vascular ADP-degrading enzyme activity. Diabetes Res Clin Pract. 1987 ; 3 (1). 9-19
119. Denke MA, Grundy SM. Comparison of effects of lauric acid and palmitic acid on plasma lipids and lipoproteins. Am J Clin Nutr. 1992 ; 56 (5). 895-898
120. Didisheim P, Mibashan RS. Activation of hageman factor (factor xii) by long-chain saturated fatty acids. Thromb Diath Haemorrh. 1963 ; 33: 346-353
121. Kok P, Kok SW, Buijs MM, et al. Enhanced circadian ACTH release in obese premenopausal women: reversal by short-term acipimox treatment. Am J Physiol Endocrinol Metab. 2004 ; 287 (5). E848 - E856
122. Nakagawa K, Yamaguchi T, Seida M, et al. Plasma concentrations of brain natriuretic peptide in patients with acute ischemic stroke. Cerebrovasc Dis. 2005 ; 19 (3). 157-164
123. Iltumur K, Yavavli A, Apak I, Ariturk Z, Toprak N. Elevated plasma N-terminal pro-brain natriuretic peptide levels in acute ischemic stroke. Am Heart J. 2006 ; 151 (5). 1115-1122
124. Giannakoulas G, Hatzitolios A, Karvounis H, et al. N-terminal pro-brain natriuretic peptide levels are elevated in patients with acute ischemic stroke. Angiology. 2005 ; 56 (6). 723-730
125. Tomita H, Metoki N, Saitoh G, et al. Elevated plasma brain natriuretic peptide levels independent of heart disease in acute ischemic stroke: correlation with stroke severity. Hypertens Res. 2008 ; 31 (9). 1695-1702
126. Kim MH, Kang SY, Kim MC, Lee WI. Plasma biomarkers in the diagnosis of acute ischemic stroke. Ann Clin Lab Sci. 2010 ; 40 (4). 336-341
127. Balion CM, Santaguida P, McKelvie R, et al. Physiological, pathological, pharmacological, biochemical and hematological factors affecting BNP and NT-proBNP. Clin Biochem. 2008 ; 41 (4-5). 231-239
128. Liu X, Jin Y, Zheng H, Chen G, Tan B, Wu B. Arginine vasopressin gene expression in supraoptic nucleus and paraventricular nucleus of hypothalamous following cerebral ischemia and reperfusion. Chin Med Sci J. 2000 ; 15 (3). 157-161
129. Liu X. An experimental study of arginine vasopressin on acute ischemic brain edema in gerbils (1) [in Chinese]. Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1992 ; 25 (4). 232-234
130. Barreca T, Gandolfo C, Corsini G, et al. Evaluation of the secretory pattern of plasma arginine vasopressin in stroke patients. Cerebrovasc Dis. 2001 ; 11 (2). 113-118
131. Liu XF, Shi YM, Lin BC. Mechanism of action of arginine vasopressin on acute ischemic brain edema. Chin Med J (Engl). 1991 ; 104 (6). 480-483
132. Dickinson LD, Betz AL. Attenuated development of ischemic brain edema in vasopressin-deficient rats. J Cereb Blood Flow Metab. 1992 ; 12 (4). 681-690
133. Ikeda Y, Toda S, Kawamoto T, Teramoto A. Arginine vasopressin release inhibitor RU51599 attenuates brain oedema following transient forebrain ischaemia in rats. Acta Neurochir (Wien). 1997 ; 139 (12). 1166-1171
134. Vallet P, Bouras C, Barberis C, Dreifuss JJ, Dubois-Dauphin M. Vasopressin binding in the cerebral cortex of the Mongolian gerbil is reduced by transient cerebral ischemia. J Comp Neurol. 1995 ; 362 (2). 223-232